Epilepsy | Pharmacor | G7 | 2014
With approximately 5 million patients diagnosed in the seven major pharmaceutical markets, epilepsy is a common, debilitating collection of seizure disorders that affect patients’ quality of life and impart a social and economic burden on patients and their families, as well as healthcare institutions. Despite the availability of numerous established antiepileptic drugs (AEDs) and the expected influx of new agents designed for the acute treatment or chronic prevention of seizures over the next decade, considerable unmet need exists in epilepsy; such needs include transformative disease-modifying therapeutics, biomarkers to guide treatment selection, and effective alternatives for the 20-30% of drug-treated patients who do not respond to current agents.
